When Pfizer Inc./BioNTech SE’s mRNA COVID-19 vaccine Comirnaty was launched, many hoped it would make its way to Indian shores sooner rather than later.
That didn’t happen as talks with the Indian government over indemnity and pricing broke down, costing the US company an opportunity to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?